Parasitic helminths and protozoa: Treasure boxes of disease modifying anti-rheumatic drugs

被引:0
|
作者
Osada, Yoshio [1 ]
Shimizu, Shoichi [1 ]
Morita, Kentaro [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Immunol & Parasitol, 1-1 Iseigaoka,Yahatanishi Ku, Kitakyushu 8078555, Japan
关键词
Parasite; Helminth; Protozoa; Immunomodulation; Schistosoma; Trichinella; Plasmodium; DMARD; Th17; Cytokine; Microbiota; Collagen; Adjuvant; COLLAGEN-INDUCED ARTHRITIS; SCHISTOSOMA-MANSONI INFECTION; AMELIORATES JOINT DISEASE; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ARTHRITIS; ADJUVANT ARTHRITIS; BONE EROSION; TNF-ALPHA; B-CELLS;
D O I
10.1016/j.parint.2024.103000
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Parasites generally survive in their hosts by employing various immunomodulation and immune evasion mechanisms. "helminth therapy" is one strategy that harnesses these parasite-specific beneficial properties for the therapeutic treatment of autoimmune and allergic diseases. Although numerous experimental reports have documented the anti-autoimmune activities of parasitic infections and parasite-derived products, the underlying mechanisms remain insufficiently elucidated due to the significant diversity among parasite species and auto- immune conditions. Rheumatoid arthritis (RA) is one of the most prevalent autoimmune disorders, presenting a substantial opportunity for the therapeutic use of parasites as novel disease-modifying antirheumatic drugs (DMARDs). In this paper, we summarize the immunomodulatory properties of parasites, focusing on their anti- arthritic mechanisms, and discuss the potential of parasite-derived products for the treatment of RA.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    STECHER, VJ
    CARLSON, JA
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1983, 18 : 171 - 179
  • [2] Pharmacogenetics of disease-modifying anti-rheumatic drugs
    Tanaka, E
    Taniguchi, A
    Urano, W
    Yamanaka, H
    Kamatani, N
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
  • [3] Disease Modifying Anti-Rheumatic Drugs Compliance Study
    Vostretsova, Kateryna
    Rogers, Pam
    Thompson, Darby J. S.
    Lacaille, Diane
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S731 - S732
  • [4] Disease-modifying anti-rheumatic drugs - Cyclosporin
    Chaudhuri, K
    Torley, H
    Madhok, R
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (09): : 1016 - 1021
  • [5] GUIDELINE ON CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Galloway, James
    RHEUMATOLOGY, 2016, 55 : 14 - 14
  • [6] DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AS A CAUSE OF IGA NEPHROPATHY
    Sulaiman, Abdullahi
    Shawwa, Khaled
    Shahrier, Amin
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S9 - S10
  • [7] New Disease modifying anti-rheumatic drugs (for Health Professionals)
    Forster, A.
    SWISS MEDICAL WEEKLY, 2009, 139 (7-8) : 4S - 4S
  • [8] PATIENT PREFERENCES IN THE CHOICE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Schiffner-Rohe, J.
    Alten, R.
    Krueger, K.
    Behmer, O. S.
    Schiffhorst, G.
    Rellecke, J.
    Nolting, H. D.
    VALUE IN HEALTH, 2014, 17 (07) : A385 - A385
  • [9] MISSED OPPORTUNITIES IN THE MONITORING OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)
    Dyaanand, H.
    Dickson, M.
    Tilley, D.
    Nisar, M.
    RHEUMATOLOGY, 2002, 41 : 43 - 43
  • [10] PATIENT BELIEFS AND PREFERENCES IN TREATMENT WITH DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Schiffner-Rohe, J.
    Alten, R.
    Krueger, K.
    Behmer, O. S.
    Schiffhorst, G.
    Rellecke, J.
    Nolting, H.
    VALUE IN HEALTH, 2015, 18 (07) : A652 - A652